FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea
26 févr. 2024 16h05 HE
|
FibroGen, Inc.
The FibroGen – AstraZeneca China Agreement for Roxadustat remains in place FibroGen to explore licensing opportunities for Roxadustat SAN FRANCISCO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- FibroGen,...
Gracell Biotechnologies Acquisition Completed
22 févr. 2024 08h45 HE
|
Gracell Biotechnologies Inc.
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, Nasdaq: GRCL), a global clinical-stage biopharmaceutical...
Gracell Biotechnologies Announces Shareholders’ Approval of Merger Agreement
20 févr. 2024 07h45 HE
|
Gracell Biotechnologies Inc.
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL), a global clinical-stage biopharmaceutical...
Viral Gastroenteritis Market Size & Share to Exceed USD 10.2 Billion by 2034, at CAGR of 4.6%. “Conquering the Waves: Breakthroughs in Viral Gastroenteritis Market Surge Toward a Healthier Tomorrow!” – PMI Leads the Way
01 févr. 2024 21h00 HE
|
PMI
Covina, Feb. 01, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the Viral Gastroenteritis Market size was valued at about USD 6.8 Billion in 2024 and expected to grow at CAGR of...
Uveal Melanoma Market Size & Share to Exceed USD 2.5 Billion by 2034, at CAGR of 5.9%. "Shining a Light on Innovation: Revolutionizing the Uveal Melanoma Market for Brighter Tomorrows" – PMI Leads the Way
01 févr. 2024 20h30 HE
|
PMI
Covina, Feb. 01, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the Uveal Melanoma Market size was valued at about USD 1.5 Billion in 2024 and expected to grow at CAGR of 5.9% to...
Use of SGLT2 Inhibitors Continues to Expand for the Treatment of Chronic Kidney Disease, with Eli Lilly/Boehringer Ingelheim’s Jardiance Making Significant Strides Following Label Expansion
03 janv. 2024 16h13 HE
|
Spherix Global Insights
EXTON, PA, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Since 2019, audited records of chronic kidney disease (CKD) non-dialysis patients has revealed an ongoing, annual uptick in the proportion of...
Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca
12 déc. 2023 02h05 HE
|
Icosavax, Inc.
Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca
Non-Steroidal Anti-Inflammatory Drugs Market Skyrockets: Witness Impressive US$ 28.7 billion by 2030 and Striking CAGR of 6.0% - By PMI
09 nov. 2023 08h30 HE
|
PMI
Covina, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Report Overview of Non-Steroidal Anti-Inflammatory Drugs Market: Non-Steroidal Anti-Inflammatory Drugs, commonly known as NSAIDs, are a class of...
Spherix Global Insights Amplifies the Lupus Patient Voice, Highlighting the Lengthy and Challenging Journey to Diagnosis and Treatment
08 nov. 2023 15h37 HE
|
Spherix Global Insights
Exton, Pennsylvania, Nov. 08, 2023 (GLOBE NEWSWIRE) -- [Exton PA, November 8, 2023] — Spherix Global Insights recently conducted research with 306 Systemic Lupus Erythematosus (SLE) patients,...
In a Push to Limit Use of Glucocorticoids, US and EU5 Rheumatologists are Increasingly Turning to GSK’s Benlysta and AstraZeneca’s Saphnelo for the Treatment of Moderate-to-Severe Systemic Lupus Erythematosus, According to Spherix Global In
04 oct. 2023 03h00 HE
|
Spherix Global Insights
Exton, Pennsylvania, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Prior to the initial approval of Benlysta in 2011, systemic lupus erythematosus (SLE) patients and prescribers had limited options for the...